Replicel Life Sciences Incis A Vancouver Based Regenerative Medicine Company Focused On Autologous Cell Therapies And Medical Devices For Aesthetic And Orthopedic Applicationsthe Company Develops Personalized Treatments Using A Patientae S Own Cells To Restore Tissue Integrity And Address Age Related Degenerationits Clinical Programs Target Conditions Related To Insufficient Healthy Cellsincluding Hair Lossskin Agingand Chronic Tendon Injuries Replicel S Product Pipeline Features Several Innovative Therapiesrch 01 Is An Autologous Cell Therapy For Androgenetic Alopeciacurrently In Pivotal Clinical Trialsrcs 01 Aims To Rejuvenate Aging Or Uv Damaged Skinwhile Rct 01 Focuses On Repairing Chronic Tendinopathy In Jointsthe Company Also Offers Dermaprecisea Can Electronic Dermal Injector Designed For Precise Delivery Of Cell Therapies And Other Substances The Company Operates As A Virtual Technology Development Organizationcollaborating With Research Institutions And Clinical Organizations To Drive Innovationreplicel Emphasizes Licensing Agreements And Co Development Partnerships To Scale Production And Distributiontargeting Aesthetic Clinicsorthopedic Centersand Medical Device Distributors In The Growing Biotechnology Market
